Loading... 2 0 5 0 false
Credit Name
Oliver Klein
Full Name
Klein, Oliver
 
Department
 
Loading... 3 0 5 0 false

Publications

Results 1-15 of 15 (Search time: 0.008 seconds).

Publication YearTitleAuthor(s)
11-Sep-2020Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers: Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial.Klein, Oliver ; Kee, Damien ; Nagrial, Adnan; Markman, Ben; Underhill, Craig; Michael, Michael; Jackett, Louise A ; Lum, Caroline; Behren, Andreas; Palmer, Jodie; Tebbutt, Niall C ; Carlino, Matteo S; Cebon, Jonathan S 
213-Jul-2020Complete response of metastatic pleomorphic dermal sarcoma to anti-PD-1 therapy.Klein, Oliver ; McTigue, C; Wong, Z W; Syme, D B; Hunter-Smith, D J
312-Jun-2020Immunotherapy of Ipilimumab and Nivolumab in patients with advanced neuroendocrine tumours: a subgroup analysis of the CA209-538 clinical trial for rare cancers.Klein, Oliver ; Kee, Damien ; Markman, Ben; Michael, Michael; Underhill, Craig R; Carlino, Matteo S; Jackett, Louise A ; Lum, Caroline; Scott, Clare L; Nagrial, Adnan; Behren, Andreas; So, Jane Yeojeong; Palmer, Jodie; Cebon, Jonathan S 
425-May-2020Sustained remission of Lynch syndrome-associated metastatic adrenocortical carcinoma following checkpoint inhibitor therapy-associated multiorgan autoimmunity.Nevgi, Aditi; Klein, Oliver ; Cheung, Ada S 
55-Sep-2019Anti-programmed cell death protein 1 (anti-PD1) immunotherapy induced autoimmune polyendocrine syndrome type II (APS-2): a case report and review of the literature.Gunjur, Ashray ; Klein, Oliver ; Kee, Damien ; Cebon, Jonathan S 
612-Nov-2018Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series.Mitchell, Emma L; Lau, Peter Kar Han; Khoo, Chloe; Liew, David F; Leung, Jessica; Liu, Bonnia ; Rischin, Adam; Frauman, Albert G ; Kee, Damien ; Smith, Kortnye; Brady, Benjamin; Rischin, Danny; Gibson, Andrew; Mileshkin, Linda; Klein, Oliver ; Weickhardt, Andrew; Arulananda, Surein; Shackleton, Mark; McArthur, Grant; Östör, Andrew; Cebon, Jonathan S ; Solomon, Benjamin; Buchanan, Russell R C ; Wicks, Ian P; Lo, Serigne; Hicks, Rodney J; Sandhu, Shahneen
72018Delayed Autoimmune Toxicity Occurring Several Months After Cessation of Anti-PD-1 Therapy.Parakh, Sagun ; Cebon, Jonathan S ; Klein, Oliver 
8Jun-2017Efficacy of anti-PD-1 therapy in patients with melanoma brain metastasesParakh, Sagun ; Park, John J; Mendis, Shehara; Rai, Rajat; Xu, Wen; Lo, Serigne; Drummond, Martin; Rowe, Catherine; Wong, Annie; McArthur, Grant; Haydon, Andrew; Andrews, Miles C; Cebon, Jonathan S ; Guminski, Alex; Kefford, Richard F; Long, Georgina V; Menzies, Alexander M; Klein, Oliver ; Carlino, Matteo S
911-Apr-2017Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''.Bowyer, Samantha; Prithviraj, Prashanth; Lorigan, Paul; Larkin, James; McArthur, Grant; Atkinson, Victoria; Millward, Michael; Khou, Muoi; Diem, Stefan; Ramanujam, Sangeetha; Kong, Ben; Liniker, Elizabeth; Guminski, Alexander; Parente, Phillip; Andrews, Miles C; Parakh, Sagun ; Cebon, Jonathan; Long, Georgina V; Carlino, Matteo S; Klein, Oliver 
1011-Apr-2017Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''.Bowyer, Samantha; Prithviraj, Prashanth; Lorigan, Paul; Larkin, James; McArthur, Grant; Atkinson, Victoria; Millward, Michael; Khou, Muoi; Diem, Stefan; Ramanujam, Sangeetha; Kong, Ben; Liniker, Elizabeth; Guminski, Alexander; Parente, Phillip; Andrews, Miles C; Parakh, Sagun ; Cebon, Jonathan S ; Long, Georgina V; Carlino, Matteo S; Klein, Oliver 
111-Feb-2017Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab.Menzies, A M; Johnson, D B; Ramanujam, S; Atkinson, V G; Wong, A N M; Park, J J; McQuade, J L; Shoushtari, A N; Tsai, K K; Eroglu, Z; Klein, Oliver ; Hassel, J C; Sosman, J A; Guminski, A; Sullivan, R J; Ribas, A; Carlino, M S; Davies, M A; Sandhu, S K; Long, G V
1210-May-2016Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy.Bowyer, S; Prithviraj, Prashanth; Lorigan, P; Larkin, J; McArthur, G; Atkinson, V; Millward, M; Khou, M; Diem, S; Ramanujam, S; Kong, B; Liniker, E; Guminski, A; Parente, P; Andrews, M C; Parakh, S ; Cebon, Jonathan S ; Long, G V; Carlino, M S; Klein, O 
137-Feb-2015Low-dose cyclophosphamide enhances antigen-specific CD4(+) T cell responses to NY-ESO-1/ISCOMATRIX™ vaccine in patients with advanced melanoma.Klein, Oliver ; Davis, Ian D; McArthur, Grant A; Chen, Li; Haydon, Andrew; Parente, Phillip; Dimopoulos, Nektaria; Jackson, Heather M; Xiao, Kun; Maraskovsky, Eugene; Hopkins, Wendie; Stan, Rodica; Chen, Weisan; Cebon, Jonathan S 
141-Jun-2011Melanoma vaccines: developments over the past 10 years.Klein, Oliver ; Schmidt, Christopher; Knights, Ashley J; Davis, Ian D; Chen, Weisan; Cebon, Jonathan S 
151-Jun-2006Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1.Nicholaou, Theo; Ebert, Lisa; Davis, Ian D; Robson, Neil; Klein, Oliver ; Maraskovsky, Eugene; Chen, Weisan; Cebon, Jonathan S